Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 20182025
- Published Date: 2020-10-18
- Report ID: 3544
- Pages: 171
-
Format:
The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults.
Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.
Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.
The global pneumonia vaccine market is segmented based on type, product, distribution channel, sector, and region. Based on type, the market is bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV). Products covered in the study include Synflorix, Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and PCV-10-SII. Based on distribution channel, the market is categorized into distribution partner companies, non-governmental organizations (NGO), and government authorities. Based on sector, the market is bifurcated into public and private. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine
By Product Type
Prevnar 13
Synflorix
Pneumovax 23
By Sector
Public
Private
By distribution channel
Distribution Partner Companies
Non-governmental Organizations (NGO)
Government Authorities
By Country
North America
Europe
Asia-Pacific
LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT (VACCINE PROVIDERS)
Glaxosmithkline plc.
LG Chem Ltd.
Merck & Co., Inc.
Panacea Biotec Limited
Pfizer Inc.
Pnuvax Incorporated
Serum Institute of India Pvt. Ltd.
Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
SK Bioscience
Walvax Biotechnology Co., Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 20162018
3.2.3. Top strategies:
3.3. Porters five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.4. Market share analysis, 2018
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in prevalence of pneumonia across the globe
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines
3.5.2. Restraints
3.5.2.1. Longer timelines required for pneumonia vaccine production
3.5.2.2. High cost associated with development of such vaccines
3.5.3. Opportunity
3.5.3.1. Development of protein-based combination pneumococcal vaccines
CHAPTER 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pneumococcal conjugate vaccine (PCV)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast
4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast
CHAPTER 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prevnar 13
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast
5.3. Synflorix
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast
5.4. Pneumovax23
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast
5.5. Pipeline Products
CHAPTER 6: PNEUMONIA VACCINES MARKET, BY SECTOR
6.1. Overview
6.1.1. Market size and forecast
6.2. Public sector
6.2.1. Market size and forecast
6.3. Private sector
6.3.1. Market size and forecast
CHAPTER 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Distribution partner companies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.3. Non-governmental Organizations (NGO)
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.4. Government Authorities
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast
CHAPTER 8: GLOBAL PNEUMONIA MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country
8.2.7.1. The U.S. Pneumonia Vaccine Market
8.2.7.1.1. Market Size and forecast, by type
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector
8.2.7.2. Canada Pneumonia Vaccine Market
8.2.7.2.1. Market Size and forecast, by type
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector
8.2.7.3. Mexico Pneumonia Vaccine Market
8.2.7.3.1. Market Size and forecast, by type
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector
8.3. Europe
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country
8.3.7.1. Germany Pneumonia Vaccine Market
8.3.7.1.1. Market Size and forecast, by type
8.3.7.1.2. Market Size and forecast, by product type
8.3.7.1.3. Market Size and forecast, by distribution channel
8.3.7.1.4. Market Size and forecast, by sector
8.3.7.2. France Pneumonia Vaccine Market
8.3.7.2.1. Market Size and forecast, by type
8.3.7.2.2. Market Size and forecast, by product type
8.3.7.2.3. Market Size and forecast, by distribution channel
8.3.7.2.4. Market Size and forecast, by sector
8.3.7.3. UK Pneumonia Vaccine Market
8.3.7.3.1. Market Size and forecast, by type
8.3.7.3.2. Market Size and forecast, by product type
8.3.7.3.3. Market Size and forecast, by distribution channel
8.3.7.3.4. Market Size and forecast, by sector
8.3.7.4. Spain Pneumonia Vaccine Market
8.3.7.4.1. Market Size and forecast, by type
8.3.7.4.2. Market Size and forecast, by product type
8.3.7.4.3. Market Size and forecast, by distribution channel
8.3.7.4.4. Market Size and forecast, by sector
8.3.7.5. Italy Pneumonia Vaccine Market
8.3.7.5.1. Market Size and forecast, by type
8.3.7.5.2. Market Size and forecast, by product type
8.3.7.5.3. Market Size and forecast, by distribution channel
8.3.7.5.4. Market Size and forecast, by sector
8.3.7.6. Rest of Europe Pneumonia Vaccine Market
8.3.7.6.1. Market Size and forecast, by type
8.3.7.6.2. Market Size and forecast, by product type
8.3.7.6.3. Market Size and forecast, by distribution channel
8.3.7.6.4. Market Size and forecast, by sector
8.4. Asia-Pacific
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast, by type
8.4.4. Market size and forecast, by product type
8.4.5. Market size and forecast, by distribution channel
8.4.6. Market size and forecast, by sector
8.4.7. Market size and forecast, by country
8.4.7.1. Japan Pneumonia Vaccine Market
8.4.7.1.1. Market Size and forecast, by type
8.4.7.1.2. Market Size and forecast, by product type
8.4.7.1.3. Market Size and forecast, by distribution channel
8.4.7.1.4. Market Size and forecast, by sector
8.4.7.2. China Pneumonia Vaccine Market
8.4.7.2.1. Market Size and forecast, by type
8.4.7.2.2. Market Size and forecast, by product type
8.4.7.2.3. Market Size and forecast, by distribution channel
8.4.7.2.4. Market Size and forecast, by sector
8.4.7.3. India Pneumonia Vaccine Market
8.4.7.3.1. Market Size and forecast, by type
8.4.7.3.2. Market Size and forecast, by product type
8.4.7.3.3. Market Size and forecast, by distribution channel
8.4.7.3.4. Market Size and forecast, by sector
8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market
8.4.7.4.1. Market Size and forecast, by type
8.4.7.4.2. Market Size and forecast, by product type
8.4.7.4.3. Market Size and forecast, by distribution channel
8.4.7.4.4. Market Size and forecast, by sector
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast, by type
8.5.4. Market size and forecast, by product type
8.5.5. Market size and forecast, by distribution channel
8.5.6. Market size and forecast, by sector
8.5.7. Market size and forecast, by country
8.5.7.1. Brazil Pneumonia Vaccine Market
8.5.7.1.1. Market Size and forecast, by type
8.5.7.1.2. Market Size and forecast, by product type
8.5.7.1.3. Market Size and forecast, by distribution channel
8.5.7.1.4. Market Size and forecast, by sector
8.5.7.2. South Africa Pneumonia Vaccine Market
8.5.7.2.1. Market Size and forecast, by type
8.5.7.2.2. Market Size and forecast, by product type
8.5.7.2.3. Market Size and forecast, by distribution channel
8.5.7.2.4. Market Size and forecast, by sector
8.5.7.3. Saudi Arabia Pneumonia Vaccine Market
8.5.7.3.1. Market Size and forecast, by type
8.5.7.3.2. Market Size and forecast, by product type
8.5.7.3.3. Market Size and forecast, by distribution channel
8.5.7.3.4. Market Size and forecast, by sector
8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market
8.5.7.4.1. Market Size and forecast, by type
8.5.7.4.2. Market Size and forecast, by product type
8.5.7.4.3. Market Size and forecast, by distribution channel
8.5.7.4.4. Market Size and forecast, by sector
CHAPTER 9: COMPANY PROFILES
9.1. GLAXOSMITHKLINE PLC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.1.5. Business performance
9.2. LG CHEM LTD.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.3. MERCK & CO., INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance
9.4. PANACEA BIOTEC LIMITED
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. PFIZER INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. PNUVAX INCORPORATED
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio
9.7. SERUM INSTITUTE OF INDIA PVT. LTD.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Product portfolio
9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Product portfolio
9.9. SK BIOSCIENCE
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Product portfolio
9.10. WALVAX BIOTECHNOLOGY CO., LTD.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product Portfolio
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
